Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice-Reference-Cited by-同舟云学术

Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice

Published:1993-11-05 Issue:5135 Volume:262 Page:907-909
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Freeman Gordon J.¹,Borriello Frank²,Hodes Richard J.³,Reiser Hans⁴,Hathcock Karen S.³,Laszlo Gloria³,McKnight Andrew J.²,Kim Jinny²,Du Lina²,Lombard David B.¹,Gray Gary S.⁵,Nadler Lee M.¹,Sharpe Arlene H.²

Affiliation:

1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115.

2. Immunology Research Division, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.

3. Experimental Immunology Branch, National Cancer Institute and National Institute on Aging, National Institutes of Health, Bethesda, MD 20892.

4. Division of Lymphocyte Biology, Dana- Farber Cancer Institute, and Department of Pathology, Harvard Medical School, Boston, MA 02115.

5. Repligen Corporation, Cambridge, MA 02139.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference22 articles.

1. BORRIELLO F unpublished data.

2. Bradley, A., Teratocarcinomas and Embryonic Stem Cells: A Practical Approach: 113 (1987).

3. FREEMAN G unpublished data.

4. FREEMAN, G.J., STRUCTURE, EXPRESSION, AND T-CELL COSTIMULATORY ACTIVITY OF THE MURINE HOMOLOG OF THE HUMAN LYMPHOCYTE-B ACTIVATION ANTIGEN-B7, JOURNAL OF EXPERIMENTAL MEDICINE 174: 625 (1991).

5. Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation

Cited by 369 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2);Journal for ImmunoTherapy of Cancer;2024-08

2. CD28 co-stimulation: novel insights and applications in cancer immunotherapy;Nature Reviews Immunology;2024-07-25

3. Two distinct subpopulations of marginal zone B cells exhibit differential antibody-producing capacities and radioresistance;Cellular & Molecular Immunology;2024-03-01

4. The Microbiome in Advanced Melanoma: Where Are We Now?;Current Oncology Reports;2023-06-03

5. Two Distinct Subpopulations of Marginal Zone B Cells Exhibit Differential Antibody-Producing Capacity and Radioresistance;2023-04-19